Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|11|1604-1607

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.11, 2014-06, pp. : 1604-1607

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ramucirumab in metastatic renal cell carcinoma: The sex, race, and age issues

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2379-2379

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1647-1655

John Wiley & Sons Inc

Access to resources Recommend Favorite

Urologic Approaches to Metastatic Renal Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 24, Iss. 2, 2001-05 ,pp. : 122-126

Karger

Access to resources Recommend Favorite

Metastatectomy prior to Immunochemotherapy for Metastatic Renal Cell Carcinoma

By  

Urologia Internationalis, Vol. 76, Iss. 3, 2006-04 ,pp. : 256-263

Karger

Access to resources Recommend Favorite

Patterns of care for metastatic renal cell carcinoma in Australia

By  

BJU INTERNATIONAL, Vol. 116, Iss. S3, 2015-10 ,pp. : 36-41

John Wiley & Sons Inc

Access to resources Recommend Favorite